Deferasirox

Sold as Defrijen, Nujade, Deferasirox cipla, Siroxtrin, Exjade

C₂₁H₁₅N₃O₄373.40 g/mol

4-[3,5-Bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid

Drag to rotate. Structure from PubChem CID 214348.

Loading Wikipedia summary

Registration

Applicants: 5
Registrations: 14
Schedule source: Consolidated Schedules 06 July 2026

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Ranbaxy Pharmaceutical (Pty) LtdCancelled	Defrijen	125, 250	520954, 520955	S4	None
Ranbaxy (SA) (Pty) LtdCancelled	Defrijen	500	520956	S4	None
Cipla Medpro (Pty) LtdCancelled	Nujade, Deferasirox cipla	90 mg, 180 mg, 360 mg	530576, 530577, 530578, 530579.576, 530580.577, 530581.578	S4	None
Trinity Pharma (Pty) Ltd	Siroxtrin	125, 250, 500	5612124, 561222, 561223	S4	PI PIL
Novartis South Africa (Pty) Ltd	Exjade	250 mg, 500 mg	A400267, A400268	S4	None

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Defrijen 125 Each Tablet contains: Deferasirox 125,0 mg	125	52095452/27/0954	Cancelled	S4	None
Defrijen 250 Each Tablet contains: Deferasirox 250 mg	250	52095552/27/0955	Cancelled	S4	None
Defrijen 500 Each Tablet contains: Deferasirox 500 mg	500	52095652/27/0956	Cancelled	S4	None
Nujade 90 MG EACH TABLET CONTAINS DEFERASIROX 90,0 mg	90 mg	53057653/27/0576	Cancelled	S4	None
Nujade 180 MG EACH TABLET CONTAINS DEFERASIROX 180,0 mg	180 mg	53057753/27/0577	Cancelled	S4	None
Nujade 360 MG EACH TABLET CONTAINS DEFERASIROX 360,0 mg	360 mg	53057853/27/0578	Cancelled	S4	None
Deferasirox 90 MG cipla EACH TABLET CONTAINS DEFERASIROX 90,0 mg	90 mg	530579.57653/27/0579.576	Cancelled	S4	None
Deferasirox 180 MG cipla EACH TABLET CONTAINS DEFERASIROX 180,0 mg	180 mg	530580.57753/27/0580.577	Cancelled	S4	None
Deferasirox 360 MG cipla EACH TABLET CONTAINS DEFERASIROX 360,0 mg	360 mg	530581.57853/27/0581.578	Cancelled	S4	None
Siroxtrin 500 EACH TABLET CONTAINS DEFERASIROX 500,0 mg	500Dispersible tablets	561212456/27//1224Approved 18 March 2025	Registered	S4	PI PIL
Siroxtrin 125 EACH TABLET CONTAINS DEFERASIROX 125,0 mg	125Dispersible tablets	56122256/27/1222Approved 18 March 2025	Registered	S4	PI PIL
Siroxtrin 250 EACH TABLET CONTAINS DEFERASIROX 250,0 mg	250Dispersible tablets	56122356/27/1223Approved 18 March 2025	Registered	S4	PI PIL
Exjade 250 MG EACH TABLET CONTAINS DEFERASIROX 250,0 mg	250 mg	A400267A40/27/0267	Registered	S4	None
Exjade 500 MG EACH TABLET CONTAINS DEFERASIROX 500,0 mg	500 mg	A400268A40/27/0268	Registered	S4	None

Regulatory status

Where S4 sits on the scale

S0S1S2S3S4S5S6S7S8

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Deferasirox

S4: Deferasirox
Consolidated Schedules 06 July 2026, line 5970

Pharmacological class: Chelating agents (versenates) as heavy metal antidotes (class 27)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Schedule verified from official documents

Schedule Verification

Siroxtrin 500, Trinity Pharma (Pty) Ltd is scheduled S4 in its official SAHPRA documents, read with 90% confidence.

Professional information (PI)For healthcare professionalsSiroxtrin 500, Trinity Pharma (Pty) Ltd Patient information leaflet (PIL)For patients and carersSiroxtrin 500, Trinity Pharma (Pty) Ltd

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles

Background